|
More
IT Supplies
Research Library
|
|
Aptuit
|
Pharmaceutical and biotech companies of all sizes are increasingly turning to third parties to execute some or all of their clinical supply activities. There is a need for these companies to control and track these activities in their information systems.
This article addresses the various methods in which the activities of third-party supply contractors and IVRS (Interactive Voice Response ...
|
|
|
Aptuit
|
The core of any good clinical supply chain system is a supply management system that addresses all of the nuances of clinical supplies. Although Clinical Supply Management is often considered a back-office business unit for a sponsor, it is almost always on the critical path of the drug development process. The efficient, accurate and timely delivery of material to the investigators is critical ...
|
|
|
Pilgrim Software, Inc
|
Quality in the Global Pharmaceutical Supply Chain
Quality in the Global Pharmaceutical Supply Chain
Supplier quality has been a prime topic at recent industry conferences. Original Equipment Manu- facturers (OEM) material suppliers and contract manufacturers attended to listen to the implica- tions and driving forces behind the scrutiny of our supply chain. Although regulations and guidelines ...
|
|
|
BioClinica, Inc.
|
Demand-planning practices for clinical supply chains aren’t healthy. Despite the prevalence of such basic demand-planning
practices, there are some companies that have developed
more sophisticated, stochastic demand-modeling
and simulation capabilities. Robust simulation and modeling of clinical trial site enrollment, coupled with efficient manufacturing of
clinical supplies and execution of ...
|
|
|
TrakLok Corporation
|
The supply chain is a critical linkage for the globalized economy, but it remains a clear and vulnerable vector for terrorism, theft, and illegal activities into and out of the country. Many products seek to address this problem, but offer little physical security, and often only offer a false sense of security. Further, many of these products offer no commercial economic incentive for adoption ...
|
|
|
|
